2019 ; Vol.29-8: 1281~1287
|Author||Yongmin Yan, Yanjing Wang, Jiali Qian, Sihui Wu, Yi Ji, Yanxiao Liu, Jian Zeng, Aihua Gong|
|Place of duty||Key Laboratory of Laboratory Medicine of Jiangsu Province, School of Medicine, Jiangsu University, Zhenjiang, 212013, Jiangsu, P.R. China|
|Title||Nattokinase Crude Extract Inhibits Hepatocellular Carcinoma Growth in Mice|
J. Microbiol. Biotechnol.2019 ;
|Abstract||Nattokinase (NK, E.C. 184.108.40.206) is a serine protease produced by Bacillus subtilis natto that
shows promise for the treatment of thrombotic disease. In this study, we assessed the effects of
NK on the development of hepatocellular carcinoma (HCC), a principal malignancy of the
liver that causes morbidity and mortality worldwide. Crude extracts of NK (NCE) were
isolated from fermentation medium by centrifugation and separated into three fractions (<10
K, 100~30 K and >30K). Orthotopic HCC mouse models were established and NCE was
administered by oral gavage. H&E staining was performed to examine the pathology of HCC
livers. Immunohistochemistry and immunofluorescence were used to evaluate FOXM1, CD31,
CD44 and vimentin expression in the liver. Compared to PBS groups, NCE increased the
survival rates of HCC-bearing mice to 31% and decreased ascites. Low-intensity ultrasound
imaging showed that the hypoechoic mass area was lower in NCE-treated mice and that tumor
growth significantly decreased. IHC staining showed that the expression of FOXM1 was
inhibited by NCE treatment. Immunofluorescence results revealed lower levels of CD31, CD44
and vimentin in the NCE groups. Taken together, these data demonstrate that NCE from
Bacillus subtilis natto improves survival and inhibits tumor growth in HCC mice.|
|Key_word||Hepatocellular carcinoma, nattokinase, tumor growth, cancer|
Nault JC, Galle PR, Marquardt JU. 2018. The role of molecular enrichment on future therapies in hepatocellular carcinoma. J. Hepatol. 69: 237-247.
Waziry R, Grebely J, Amin J, Alavi M, Hajarizadeh B, George J, et al. 2017. Survival following hospitalization with hepatocellular carcinoma among people notified with hepatitis B or C virus in Australia (2000-2014). Hepatol. Commun. 1: 736-47.
Najjar M, Agrawal S, Emond JC, Halazun KJ. 2018. Pretreatment neutrophil-lymphocyte ratio: useful prognostic biomarker in hepatocellular carcinoma. J. Hepatocell. Carcinoma 5: 17-28.
Giard JM, Mehta N, Dodge JL, Roberts JP, Yao FY. 2018. Alpha-fetoprotein Slope >7.5 ng/ml/month predicts microvascular invasion and tumor recurrence after liver transplantation for hepatocellular carcinoma. Transplantation 102: 816-822.
Weng Y, Yao J, Sparks S, Wang KY. 2017. Nattokinase: An oral antithrombotic agent for the prevention of cardiovascular disease. Int. J. Mol. Sci. 18.
Selvarajan E, Bhatnagar N. 2017. Nattokinase: an updated critical review on challenges and perspectives. Cardiovasc. Hematol. Agents Med. Chem. doi: 10.2174/1871525716666171207153332. [Epub ahead of print]
Kotb E. 2014. The biotechnological potential of fibrinolytic enzymes in the dissolution of endogenous blood thrombi. Biotechnol. Prog. 30: 656-672.
Fujita M, Ohnishi K, Takaoka S, Ogasawara K, Fukuyama R, Nakamuta H. 2011. Antihypertensive effects of continuous oral administration of nattokinase and its fragments in spontaneously hypertensive rats. Biol. Pharm. Bull. 34: 1696-1701.
Kim JY, Gum SN, Paik JK, Lim HH, Kim KC, Ogasawara K, et al. 2008. Effects of nattokinase on blood pressure: a randomized, controlled trial. Hypertens. Res. 31: 1583-1588.
Takano A, Hirata A, Ogasawara K, Sagara N, Inomata Y, Kawaji T, et al. 2006. Posterior vitreous detachment induced by nattokinase (subtilisin NAT): a novel enzyme for pharmacologic vitreolysis. Invest. Ophthalmol. Vis. Sci. 47: 2075-2079.
Fadl NN, Ahmed HH, Booles HF, Sayed AH. 2013. Serrapeptase and nattokinase intervention for relieving Alzheimer’s disease pathophysiology in rat model. Hum. Exp. Toxicol. 32: 721-735.
Chand V, Pandey A, Kopanja D, Guzman G, Raychaudhuri P. 2019. Opposing Roles of the Fork-head box genes FoxM1 and FoxA2 in Liver Cancer. Mol. Cancer Res. 17: 1063-1074.
Guo D, Song X, Guo T, Gu S, Chang X, Su T, et al. 2018. Vimentin acetylation is involved in SIRT5-mediated hepatocellular carcinoma migration. Am. J. Cancer Res. 8: 2453-2466.
Wada F, Koga H, Akiba J, Niizeki T, Iwamoto H, Ikezono Y, et al. 2018. High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: potential targets by sulfasalazine. Cancer Sci. 109: 2801-2810.
Milewski D, Balli D, Ustiyan V, Le T, Dienemann H, Warth A, et al. 2017. FOXM1 activates AGR2 and causes progression of lung adenomas into invasive mucinous adenocarcinomas. PLoS Genet. 13: e1007097.
Zhang Bin, Liu Yuwan, Ji Qian, Zhao Mengmeng, Zeng Jian, Liu Lihua et al. 2017. Nattokinase Crude Extract Enhances Cutaneous Wound Healing. J. Biomater. Tissue Eng. 7: 1281-1286.
Man LL, Xiang DJ, Zhang CL. 2019. Strain screening from traditional fermented soybean foods and induction of Nattokinase production in Bacillus subtilis MX-6. Probiotics Antimicrob. Proteins 11: 283-294.
Yin Y, L iu L , Zhao Z, Yin L , Bauer N, Nwaeburu CC, et al. 2018. Simvastatin inhibits sonic hedgehog signaling and stemness features of pancreatic cancer. Cancer Lett. 426: 14-24.
Ma C, Wang F, Han B, Zhong X, Si F, Ye J, et al. 2018. SAL L 1 functions as a tumor suppressor in b reast cancer by regulating cancer cell senescence and metastasis through the NuRD complex. Mol. Cancer 17: 78.
Chatterji P, Rustgi AK. 2018. RNA Binding proteins in intestinal epithelial biology and colorectal cancer. Trends Mol. Med. 24: 490-506.
Incio J, L i gibel J A, M cManus D T, Suboj P , Jung K , Kawaguchi K, et al. 2018. Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2. Sci. Transl. Med. 10(432).
Vaahtomeri K, Karaman S, Makinen T, Alitalo K. 2017. Lymphangiogenesis guidance by paracrine and pericellular factors. Genes Dev. 31: 1615-1634.
Murgai M, Ju W, Eason M, Kline J, Beury DW, Kaczanowska S, et al. 2017. KLF4-dependent perivascular cell plasticity mediates pre-metastatic niche formation and metastasis. Nat. Med. 23: 1176-90.
Suzuki Y, Kondo K, Matsumoto Y, Zhao BQ, Otsuguro K, Maeda T, et al. 2003. Dietary supplementation of fermented soybean, natto, suppresses intimal thickening and modulates the lysis of mural thrombi after endothelial injury in rat femoral artery. Life Sci. 73: 1289-1298.
Yao S , Fan LY, L am EW. 2 017. The FOXO3-FOXM1 axis: A key cancer drug target and a modulator of cancer drug resistance. Semin. Cancer Biol. 50: 77-89.
Yue M, L i S, Y an G , Li C, K ang Z. 2 018. P aeoniflorin inhibits cell growth and induces cell cycle arrest through inhibition of FoxM1 in colorectal cancer cells. Cell Cycle 17: 240-249.
Zaiden M, Feinshtein V, David A. 2017. Inhibition of CD44v3 and CD44v6 function blocks tumor invasion and metastatic colonization. J. Control. Release 257: 10-20.
Nodale C, Sheffer M, Jacob-Hirsch J, Folgiero V, Falcioni R, Aiello A, et al. 2012. HIPK2 downregulates vimentin and inhibits breast cancer cell invasion. Cancer Biol. Ther. 13: 198-205.
Zhang X, Fournier MV, Ware JL, Bissell MJ, Yacoub A, Zehner ZE. 2009. Inhibition of vimentin or beta1 integrin reverts morphology of prostate tumor cells grown in laminin-rich extracellular matrix gels and reduces tumor growth in vivo. Mol. Cancer Ther. 8: 499-508.